Aditya Bardia, ESMO 2020 – Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer: the ASCENT Trial
touchONCOLOGY meets with Dr Aditya Bardia at the Virtual 2020 ESMO Congress to discuss the recently presented data from the ASCENT trial, and the role sacituzumab govitecan may play in the treatment of previously-treated metastatic triple-negative breast cancer. The late-breaking abstract ‘ASCENT: A randomized phase 3 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)‘ (LBA17) was presented at the Virtual 2020 ESMO Congress, 12–21 September 2020.
Questions
- Why is triple-negative breast cancer so hard to treat, and what is the current standard of care for patients with metastatic disease? (0:15)
- Could you tell us a little about sacituzumab govitecan-hziy and its mechanism of action? (1:15)
- What were the aims and design of the ASCENT study? (2:48)
- What were the major efficacy and safety findings of the study? (3:29)
- How will these findings impact on clinical practice and what future studies are planned? (5:07)
Speaker Disclosures: Dr Aditya Bardia declares the following. Consultant/advisor for Biotheranostics, Daiichi Pharma/AstraZeneca, Genentech, Immunomedics, Lilly, Novartis, Pfizer, Puma Biotechnology, Merck, Philipps, Radius Health, Sanofi, Spectrum Pharmaceuticals, Foundation Medicine, and Taiho Pharmaceutical; research funding (to institution) from Biothernostics, Genentech/F. Hoffman-La Roche, Immunomedics, Innocrin Pharmaceuticals, Merck, Mersana Therapeutics, Novartis, Pfizer, Radius Health, and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. The ASCENT trial was sponsored by Immunomedics Inc.
Filmed in coverage of the Virtual 2020 ESMO Congress.
